ACTengine® IMA203 Combined With mRNA-4203

This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

Trial Details

NCT ID
NCT06946225
Phase
PHASE1
Sponsor
Immatics US, Inc.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • IMA203
  • mRNA-4203
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New York, New York, United States|40.71427,-74.00597
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Pathologically confirmed and documented cutaneous melanoma (CM) or synovial sarcoma (SS) with unresectable or metastatic disease
  • HLA-A\*02:01 positive
  • Adequate selected organ function per protocol
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →